Crescent Biopharma (CBIO) Non-Current Deffered Revenue (2013 - 2018)
Crescent Biopharma (CBIO) reported Non-Current Deffered Revenue of $611623.0 for Q4 2018, down 13.49% year-over-year from $707003.0 in Q4 2017, and down 4.39% quarter-over-quarter from $639733.0 in Q3 2018.
Crescent Biopharma (CBIO) Non-Current Deffered Revenue (2013 - 2018) Analysis & Trends
Crescent Biopharma (CBIO) has 6 years of Non-Current Deffered Revenue data on file, last reported at $611623.0 in Q4 2018.
- Non-Current Deffered Revenue for Q4 2018 came in at $611623.0, down 13.49% year-over-year; the trailing twelve-month figure through Dec 2018 was $611623.0 (down 13.49% YoY), and the FY2018 annual result was $611623.0, down 13.49% from the prior year.
- Non-Current Deffered Revenue declined to $611623.0 in Q4 2018 per CBIO's latest filing, from $639733.0 in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $841426.0 in Q3 2016 and troughed at $9709.0 in Q3 2014.
- A 5-year average of $473283.4 and a median of $639733.0 in 2018 frame the typical range for Non-Current Deffered Revenue.
- The sharpest annual moves came in 2015 and 2016: Non-Current Deffered Revenue slipped 27.5% in 2015, then surged 2739.56% in 2016.
- A 5-year view of Non-Current Deffered Revenue shows it stood at $97012.0 in 2014, then soared by 151.15% to $243647.0 in 2015, then surged by 209.29% to $753579.0 in 2016, then slipped by 6.18% to $707003.0 in 2017, then slipped by 13.49% to $611623.0 in 2018.
- Business Quant data shows CBIO's Non-Current Deffered Revenue at $611623.0 in Q4 2018, $639733.0 in Q3 2018, and $663745.0 in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Crescent Biopharma | 486.92 Mn | 297.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 611,623.00 |
| Sep 30, 2018 | 639,733.00 |
| Jun 30, 2018 | 663,745.00 |
| Mar 31, 2018 | 685,689.00 |
| Dec 31, 2017 | 707,003.00 |
| Sep 30, 2017 | 801,058.00 |
| Jun 30, 2017 | 742,584.00 |
| Mar 31, 2017 | 824,653.00 |
| Dec 31, 2016 | 753,579.00 |
| Sep 30, 2016 | 841,426.00 |
| Jun 30, 2016 | 799,478.00 |
| Mar 31, 2016 | 250,143.00 |
| Dec 31, 2015 | 243,647.00 |
| Sep 30, 2015 | 186,526.00 |
| Jun 30, 2015 | 28,155.00 |
| Dec 31, 2014 | 97,012.00 |
| Sep 30, 2014 | 9,709.00 |
| Jun 30, 2014 | 38,837.00 |
| Mar 31, 2014 | 67,785.00 |
| Dec 31, 2013 | 96,756.00 |